Chair’s Opening Remarks: The Breakthrough in mRNA/DNA LNP Innovations – Low N/P ratio, Nontoxic, and High Transfection Efficiency

Time: 8:30 am
day: Day One


  • Overview of Me-Too LNPs with the conclusion that the Me-Too LNPs do not meet with the needs of rapidly developed genetic vaccines and therapeutics
  • Share Cureport’s novel strategies of LNP innovations
  • Compare the key differences between the novel LNP and Me-Too LNPs
  • Share the in vitro and in vivo data of the novel LNPs